Loading stock data…
PolyPid Ltd (PYPD)
$4.97+0.22 (+4.63%)
After Hours$5.02+0.05 (+1.01%)· Last close Jun 29
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
PolyPid Ltd. in the Healthcare sector is trading at $4.97 with a market capitalization of $90M. Wall Street consensus targets $12.25 (4 analysts), implying a +146.5% move over the next 12 months. The stock is currently near its 52-week high of $5.24, remaining 18.9% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +146.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$7.76M↑ | -$8.53M↓ | -$7.46M↑ | -$9.40M↓ | -$7.58M |
| Net Income | -$7.73M↑ | -$8.47M↓ | -$7.45M↑ | -$9.98M↓ | -$8.27M |
Peer Comparison
JNJUNHPFE
Fundamentals
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$90.12M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-383.02%
Volume
Today's trading volume
418,226
Recent News
PolyPid Ltd (PYPD) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
PolyPid Ltd (PYPD) progresses with NDA submission and strategic partnerships, despite reporting a net loss and decreased cash reserves.
PolyPid Ltd. Q1 2026 Earnings Call Summary
Moby summary of PolyPid Ltd.'s Q1 2026 earnings call
PolyPid (PYPD) Q1 2026 Earnings Transcript
Yehuda Leibler: Thank you, operator, and thank you all for joining PolyPid's First Quarter 2026 Earnings Conference Call. Joining me on the call today will be Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid; Jonny Missulawin, PolyPid's Chief Financial Officer; and Ori Warshavsky, Chief Operating Officer, U.S. of PolyPid.
PolyPid Q1 Earnings Call Highlights
PolyPid (NASDAQ:PYPD) said its first quarter marked a transition from late-stage clinical development toward regulatory submission and commercial preparation for D-PLEX100, its lead product candidate for preventing surgical site infections in abdominal colorectal surgery. Chief Executive Officer Di
PolyPid Q1 2026 Earnings Call: Complete Transcript
PolyPid (NASDAQ:PYPD) held its first-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. The full earnings call is available at https://edge.media-server.com/mmc/p/w3mvdb4o/ Summary PolyPid reported a net loss of $7.7 million for Q1 2026, an improvement from a loss of $8.3 million in Q1 2025, with operating expenses showing a